On the sidelines of the Vietnam International Sourcing Fair (VIS) 2025, and with support from the Vietnam Trade Office in Sweden and the Latvian Chamber of Commerce and Industry (LCCI), a Latvian business delegation—including Lotos Pharma Ltd.—visited Medochemie (Far East) Ltd. at the Vietnam–Singapore Industrial Park II (VSIP II) in Binh Duong. The visit aimed to better understand Vietnam’s investment climate, assess pharmaceutical production capacity, and discuss opportunities for cooperation and partial production relocation to serve the Latvian, Baltic, and broader export markets.
During the working session, Medochemie showcased its GMP-WHO/EU-certified manufacturing system, comprising five production facilities in Vietnam. These include lines for non-beta-lactam tablets and capsules, cephalosporin injections, liquid and semi-solid preparations, and a new oral B plant commissioned in 2024, with a combined design capacity of up to billions of dosage units annually across various therapeutic segments.
The Latvian side praised Medochemie’s production capabilities and quality control, noting the increasing challenges in labor, costs, and expansion capacity in Europe. They expressed interest in contract manufacturing, OEM partnerships, and potential investment in Vietnam to boost output and optimize costs. The delegation also sought to learn from Medochemie’s experience in digitalization, automation, and supply-chain management to meet stringent EU market standards.
Within the delegation, Lotos Pharma Ltd. presented its OTC/health supplement product orientation and R&D–manufacturing strengths in Latvia (founded in 2013, with a GMP-certified facility in Mārupe). The company highlighted its need to connect with suppliers of raw materials and packaging and to explore joint product development and contract manufacturing in Vietnam.
This visit highlighted Vietnam’s advantages in industrial infrastructure, supply-chain depth, and pharmaceutical quality standards, while opening up promising prospects for Latvian enterprises to partner with Binh Duong’s pharmaceutical and biomedical ecosystem. Both sides agreed to maintain technical and commercial dialogue to evaluate specific forms of cooperation in the next phase.